Eye Surgery Abroad in 2026: which country for which problem
Every published "best countries for eye surgery" round-up answers a question almost nobody actually has. They rank countries, by price, on the assumption that one destination is best for everything from a routine cataract to an orbital decompression. That is not how eye surgery works. A cataract with a monofocal lens and a failing corneal graft are different purchases with different failure modes, and the country that is right for one can be a poor choice for the other. This page is organised the other way round — by what is wrong with your eye — and it says where China loses as plainly as where it wins. If you want the short version: India is cheapest, Korea and Thailand are the easiest to be a patient in, Turkey is the best-packaged and the shortest flight for most of Europe, China's case is subspecialty depth and drug pricing, and for a large share of readers the correct answer is your own health system.
Choose the destination from the diagnosis, not the price list. Routine cataract, funded at home → stay home. Routine cataract, self-paying on the tightest budget → India. Premium-lens cataract → run the arithmetic; the upgrade fee at home is often the real comparator. Corneal, orbital, oculoplastic, complex vitreoretinal or paediatric disease → compare institutions, not countries, and China's large tertiary eye hospitals compete seriously here. Conditions treated with expensive biologics → the comparison is a drug price, and it can run either way. Anything urgent → the nearest ophthalmology service, today. Laser vision correction is a different market with its own economics — that belongs on our sister site rather than this page.
Is it urgent? Sudden loss of vision, a curtain or shadow moving across your field, a shower of new floaters or flashes, a painful red eye, or colours looking washed out in one eye are all reasons to be examined where you are, this week. No arrangement anyone can make abroad is faster than the ophthalmology service nearest to you, and the time spent comparing destinations is time the eye does not have.
Is it funded where you live? A great deal of eye surgery is paid for at home by systems that readers forget to check before pricing a trip — cataract surgery with a standard lens under most national systems and under US Medicare, medically necessary glaucoma surgery, cross-linking for documented keratoconus progression under most US commercial plans, thyroid-eye-disease biologics under prior authorisation. Our country-by-country coverage comparison goes through six systems in detail. Check yours before you price a flight.
Why China is absent from every "best destinations" list
It is a fair question and it deserves a direct answer, because the absence is conspicuous. Search for the best countries for cataract or eye surgery abroad and you will reliably get India, Turkey, Thailand, Mexico, Singapore, South Korea and Spain. China appears in none of them.
The reason is that those lists rank medical-tourism industries, and China does not have one in the sense the lists measure. Turkey reported roughly 1.4 million health-tourism visitors and about US$3.0 billion in health-tourism revenue in 2025. Korea reported about 1.17 million foreign patients in 2024, rising past two million in 2025 — the figures are published because inbound patients are an export sector both governments actively promote. China publishes no comparable inbound eye-surgery figure and runs no equivalent promotion. The aggregators, ranking sites and package brokers who assemble those articles work on referral relationships with clinics that pay to be listed; Chinese public tertiary hospitals do not participate in that market at all.
So the absence tells you something real, and it is worth taking seriously: going to China for eye surgery is less convenient. There is less inbound infrastructure, less English packaging, no comparison portal, and fewer people who have done it before you to ask. What the absence does not tell you is anything about surgical capability. Chinese eye hospitals are among the highest-volume institutions in the world because they serve a domestic population of 1.4 billion people, and the units that international patients would actually use are the same ones that Chinese patients travel across provinces to reach. Read the missing entry as a warning about convenience, not about competence — and if convenience is what you are buying, one of the countries on those lists may genuinely be the better choice for you.
Match the destination to the problem
The table below is the core of this page. It is written from the diagnosis outward, and it hands several rows to other countries and several more back to your own health service.
| What you actually have | Where the strongest case sits | Why |
|---|---|---|
| Cataract, standard monofocal lens, funded at home | Stay home | Funded almost everywhere; the residual out-of-pocket is usually smaller than the airfare |
| Cataract, monofocal, self-paying, lowest possible price | India | Domestic list prices are the lowest published anywhere at scale; enormous routine volume |
| Cataract with a premium EDOF or trifocal lens | Genuinely open | Compare the lens upgrade fee at home against the whole price abroad — often much closer than it looks |
| Keratoconus, cross-linking, ring segments | Home first if insured; otherwise China or India | Covered by most US commercial plans on documented progression; a small-ticket procedure that may not justify a flight alone |
| Corneal transplant, graft failure, complex ocular surface | Compare institutions | Tissue availability and lifelong rejection surveillance dominate; a named home corneal specialist matters more than the country |
| Orbital disease, thyroid eye disease, oculoplastics | China competitive; Korea for aesthetic-led lid work | Staged orbital rehabilitation needs a high-volume orbital unit; China also licenses a domestic IGF-1R antibody at a fraction of the US price |
| Complex vitreoretinal surgery | Compare institutions | Outcome tracks the individual surgeon's case-mix, not the national average — and gas tamponade grounds you for weeks |
| Glaucoma — drops, laser, monitoring | Stay home | A lifelong pressure-control relationship with a reachable doctor beats a one-off price |
| Glaucoma — incisional surgery or MIGS, self-paying | China or India | Theatre-time-dominated procedures, where cost structures genuinely differ |
| Wet AMD, DME, RVO — injections | Usually stay home | Cadence, not episode; and the bill is a drug price that can favour your home country |
| Paediatric eye disease | Compare institutions; expect to stay longer | Follow-up density is high and amblyopia management is a years-long local project |
| Easiest possible patient experience, price secondary | Korea or Thailand | The most developed international-patient services in Asia, English-first, hotel-standard |
| Short flight from Europe or the Gulf, all-inclusive package | Turkey | Mature package market, 3–5 hours from most of Europe, cheap to return if reviewed |
| Laser vision correction (LASIK, SMILE, ICL) | Different market | Refractive surgery has its own economics and its own destinations — see lasikinchina.com |
Two rows deserve emphasis because they are the ones a facilitator would quietly drop. Routine cataract surgery funded at home should be done at home, and that covers a very large share of the people who read pages like this one. And chronic conditions — glaucoma, diabetic macular oedema, wet AMD — belong with a doctor you can reach, because the value in them is continuity and not the unit price of any single treatment.
The test that decides whether a cross-border price comparison means anything
This is the most useful idea on the page, and it explains most of the exceptions above. Before comparing a procedure's price between two countries, ask one question:
Where the bill is dominated by theatre time — surgeon hours, nursing, anaesthesia, equipment amortisation, ward stay — the cost gap between a high-income country and a middle-income one is structural and reliable. Vitrectomy, orbital decompression, strabismus surgery, trabeculectomy and transplant surgery all behave this way. Where the bill is dominated by a consumable — a drug vial, a premium intraocular lens, a per-case platform licence — the gap depends entirely on what that item costs in each country, and it can invert.
The clearest inversion in eye care is anti-VEGF injection therapy. An injection is five minutes of clinic time and one vial; the procedure around the vial is much the same everywhere. In the United States and several national systems, off-label repackaged bevacizumab is a mainstay of retinal practice at roughly $70 a dose against roughly $1,700–1,900 for licensed agents — so for a patient on bevacizumab, flying anywhere for injections adds cost rather than saving it. We set that out in full on the diabetic retinopathy page, and it is the reason the table above sends injection patients home.
Premium intraocular lenses are the same shape in a milder form. A trifocal lens is a manufactured article sold internationally, so the fee difference between countries narrows as the lens becomes a larger share of the bill. That is precisely why the right comparison for a premium-lens cataract is usually your own surgeon's upgrade fee against the whole price abroad, rather than total against total — the arithmetic is worked through on our cataract cost page.
Run the test on any destination page you read. If the procedure is theatre-time-dominated, a large advertised saving is plausible. If it is consumable-dominated and the page still advertises the same saving, the page has not done the arithmetic.
Where China genuinely loses
A destination comparison written by a Chinese medical-travel concierge is worth nothing unless it is willing to lose rows. Here are the ones we lose.
India wins on price, and on routine cataract volume
Indian hospitals publish domestic cataract pricing from roughly ₹25,000–55,000 per eye for phacoemulsification with a monofocal lens and roughly ₹85,000–160,000 per eye for laser-assisted surgery with a premium multifocal or trifocal lens — on the order of US$290–630 and US$970–1,830 at mid-2026 rates. International-patient packages at the larger private hospitals sit above those domestic list prices, which is why cross-country tables tend to show India higher than an Indian resident would recognise; even so, nothing beats the Indian floor.
India also does proportionally more cataract surgery than China. Its national blindness-control programme has recorded on the order of 6.6 million cataract operations in a year — against a population near 1.45 billion, a cataract surgical rate in the region of 4,500–4,700 per million. China's reported rate passed 3,000 per million by the end of 2020, roughly double its 2015 figure, with a national target of 3,500 per million for the end of 2025. On the routine-volume argument, India is ahead, and any page telling you China leads the world in cataract surgery per head has not checked.
Korea and Thailand win on the experience of being a patient
Korea's international-patient system is the most developed in Asia: dedicated coordinators, interpreters, hotel-standard facilities, and a government that counts foreign patients as an export statistic — more than two million of them in 2025. Thailand's large international hospitals have been doing English-first inpatient care for decades. If you want the process to feel frictionless, if you are travelling alone, or if you are nervous about being in a hospital where you cannot read the signage, that is worth paying a premium for and both countries deserve the reputation.
Korean prices for cataract and general ophthalmic surgery sit well above Chinese ones, and Korea's strength is concentrated in aesthetic and refractive work rather than complex medical eye disease. For periocular aesthetic surgery in particular, Korea is a reasonable first call and we would say so.
Turkey wins on packaging and on the flight
For a reader in Europe, the Gulf, North Africa or the Balkans, Istanbul is three to five hours away and the package market there is mature: a single quoted number covering transfers, hotel, interpretation and the procedure, from clinics that have handled thousands of foreign patients. The ability to return cheaply if something needs reviewing is a real clinical advantage, not just a convenience — and it is the single biggest structural disadvantage of any destination twelve hours away by air. If your procedure is straightforward and you live within a short flight of Istanbul, the comparison you should be running is a Turkish package against your own private sector.
Your own health system wins more often than any of us
Documented on the six systems we have examined in detail: the Dutch eigen risico is an annual €385 across all care rather than a per-eye charge; Belgium leaves roughly €200 per eye for a monofocal cataract with a contracted surgeon; Indonesia's BPJS covers cataract surgery and a standard lens in full once the acuity threshold is met; Hong Kong's Cataract Surgeries Programme caps the patient's share at about US$1,025, at or below our own monofocal range before travel. For those readers the correct advice is to stay home, and we give it on the cost pillar.
And distance costs everyone something
Whatever destination you choose, the routine post-operative review at week four and month three happens somewhere else, with someone who did not perform the surgery. That is manageable and it is managed every day — but it is a real cost, it is not on any price list, and it is worse the further you fly.
Where China is genuinely the better answer
Three cases, and they are narrower than a marketing page would claim.
Subspecialty depth on one campus. China's leading eye institutions are single-specialty hospitals of a scale that has few parallels — a cornea service, an orbital service, a glaucoma service, a paediatric service and several retinal teams operating in the same building, seeing case volumes that only a very large domestic population generates. For an ordinary cataract that is irrelevant. For an eye that has already had two operations, for a graft that is failing, for orbital disease needing staged rehabilitation, or for anything a general ophthalmologist has described as unusual, the ability to have several subspecialties look at the same eye in one week is the argument. Our hospitals guide names the institutions and what each is strong at.
Drug pricing on conditions treated with biologics. This is the consumable test running in our favour for once. China licensed a domestic IGF-1R antibody for thyroid eye disease in March 2025; after national price negotiation the reported per-vial price puts a full course near US$12,400–13,200 in drug cost against a published US originator course price of about US$146,000. The thyroid eye disease page works through that, including the two caveats — China's reimbursement percentages apply to enrollees of its national scheme and not to visitors, and a licence is not the same thing as stock on the shelf.
Premium lens tiers at non-premium prices. Where a Western private quote separates a modest surgical fee from a large lens upgrade, the Chinese whole-price for the same lens class is often close to the upgrade fee alone. That is a genuine gap and it is the one cataract case where travelling regularly makes sense.
The four costs no round-up prices
- The second trip. Staged work is common in eye surgery — the second eye, an adjustable suture check, a lens exchange, orbital rehabilitation that runs decompression then alignment then lids, months apart. Price the itinerary, not the procedure.
- The complication that is nobody's fault. Most complications are managed and most eyes do well, but a proportion of patients need an unplanned procedure or an extended stay. Ask, in writing, who pays for it and who provides it — at home and abroad.
- The reimbursement route that does not exist. The EU's cross-border healthcare directive lets an EU or EEA resident be treated in another member state and reclaim at home rates; it does not extend to China or to any other non-EEA country. US Medicare does not pay for care outside the United States except in three narrow border and shipboard situations. Australian Medicare and Canadian provincial plans do not fund elective treatment overseas. Whatever you spend abroad, in most cases you spend it once and alone — see our insurance, HSA/FSA and records guide for the routes that do exist.
- The records you leave with. An operative note, the implant model and serial number, drug names and lot numbers, and imaging in a format your own ophthalmologist can open are what make the follow-up work. They are free if you ask before discharge and close to unobtainable a year later from another continent.
Six questions to ask any destination
Country-neutral, and the answers are more diagnostic than any ranking.
- Who operates, and what do they do all day? A named surgeon, their subspecialty, and their annual volume of your specific procedure.
- What is in the price, and what would be added? Ask for the named additions — a different lens, a second procedure, an extra night, imaging repeated on arrival.
- What happens if there is a complication or a repeat is needed? Who provides it, who pays, and for how long does that hold.
- What records will I leave with? See the list above; ask before you book, not at discharge.
- Who reviews me at home, and have they agreed? For anything needing surveillance — grafts, glaucoma, retina — this should be arranged before you fly.
- What is the plan if I need to come back? Cost, timing, and whether the original fee covers any of it.
A destination that answers all six in writing is a better bet than a cheaper one that answers three. That test disqualifies a certain amount of what is marketed in every country on this page, ours included, and it is the reason we publish the questions rather than the rankings.
Frequently asked questions
Which country is cheapest for eye surgery?
India, for most of the common procedures, and it is not particularly close. Indian hospitals publish domestic cataract prices from roughly ₹25,000–55,000 per eye for phacoemulsification with a monofocal lens and roughly ₹85,000–160,000 per eye for laser-assisted surgery with a premium multifocal or trifocal lens — on the order of US$290–630 and US$970–1,830 at mid-2026 exchange rates. Packages quoted to international patients at the larger private hospitals sit above those domestic list prices, which is why cross-country tables usually show India higher than an Indian resident would recognise. The honest position is that no destination beats India on the headline number for routine work, so if the cheapest possible price is your only criterion, the answer is India and you can stop reading. Price is rarely the only criterion once the diagnosis is anything other than a straightforward cataract.
Why is China missing from the lists of best countries for eye surgery?
Because those lists rank medical-tourism industries, and China does not have one in the sense the lists measure. Turkey reported about 1.4 million health-tourism visitors and roughly US$3.0 billion in health-tourism revenue in 2025, and Korea reported about 1.17 million foreign patients in 2024 rising past two million in 2025. Both governments publish those figures because inbound patients are an export sector they promote. China publishes no comparable inbound eye-surgery figure and runs no equivalent promotion, so the aggregators, ranking sites and package brokers that assemble those round-ups have nothing to list and no commission relationship to list it for. The absence is a fact about marketing infrastructure, not about surgical capability — Chinese eye hospitals are among the highest-volume in the world because they serve a domestic population of 1.4 billion. Read it as a warning about convenience, not about competence.
Does China do more eye surgery than India?
Not on cataract, which is the volume benchmark. India's national blindness-control programme has recorded on the order of 6.6 million cataract operations in a year, which against a population near 1.45 billion is a cataract surgical rate in the region of 4,500–4,700 per million people. China's reported cataract surgical rate passed 3,000 per million by the end of 2020 — roughly double its 2015 figure — and the national eye-health plan set a target of 3,500 per million for the end of 2025. So India performs proportionally more cataract surgery than China does, and any page claiming China leads the world on cataract volume per head is wrong. What China's numbers do support is a different claim: enormous absolute throughput concentrated in a small number of very large tertiary institutions, which is what matters for unusual and complex cases rather than for routine ones.
Is it cheaper to have eye surgery in China or Turkey?
For most surgical eye procedures the Chinese fee schedule sits below the Turkish one, but the comparison that decides it is rarely the surgical fee. Turkey's advantage is packaging and proximity: an all-inclusive quote covering transfers, hotel and interpretation, from a clinic three to five hours' flight from most of Europe and the Gulf, with a mature broker industry to arrange it. For a reader in London, Frankfurt or Dubai, the flight difference alone can be worth more than the fee difference, and the ability to return cheaply if something needs reviewing is worth more still. The Chinese case is not the headline price. It is subspecialty depth on one campus and drug pricing on the conditions treated with expensive biologics. If the procedure is a straightforward one and you live within a short flight of Istanbul, the sensible comparison is a Turkish package against your own private sector, not against us.
When should I not travel abroad for eye surgery at all?
Four situations, and between them they cover most readers. First, when your own system funds the operation: a monofocal cataract in the Netherlands, Belgium, Indonesia or on the NHS, glaucoma treatment or a documented-progression cross-linking under most US commercial plans, thyroid-eye-disease biologics under Medicare Part B prior authorisation. Second, when the condition is urgent — sudden vision loss, a curtain or shadow across the field, a painful red eye, new flashes and floaters, changing colour perception — all of which need assessment where you are, this week, not a flight. Third, when the treatment runs on a cadence rather than in an episode: anti-VEGF injections every four to eight weeks and infusion courses spanning months cannot be compressed into a trip. Fourth, when the saving is smaller than the cost of the second trip you may need. Travel earns its place for episodic surgical work with a defined end point, in people who are self-paying or facing a deductible larger than the procedure.
Will my insurance pay for eye surgery in another country?
Almost certainly not in the way people hope, and this is where cross-border comparisons quietly mislead. US Medicare does not pay for care received outside the United States except in three narrow border and cruise-ship situations. US commercial plans vary and generally require you to pay the foreign hospital yourself and claim afterwards, at out-of-network rates and with no guarantee of the amount. The European Union's cross-border healthcare directive, which lets an EU resident be treated in another member state and claim reimbursement at home rates, applies to treatment provided within the EU and EEA — China is outside it, so it offers a reader in Ireland or Poland nothing at all. Australian Medicare and Canadian provincial plans likewise do not fund elective treatment overseas. The realistic financial routes are self-payment, a US health savings or flexible spending account where the expense qualifies, and in some cases the medical-expense deduction. Our insurance, HSA and records guide covers the mechanics; confirm your own position with your plan administrator or insurer before you travel.
Is South Korea better than China for eye surgery?
Better at some things and dearer at most. Korea's international-patient infrastructure is the most polished in Asia — coordinators, interpreters, hotel-standard facilities, a government that counts and courts foreign patients, and by 2025 more than two million of them a year. For eyelid and periocular aesthetic work, and for anyone who values the experience of being a patient there, that is a real advantage and worth paying for. Korean prices for cataract and general ophthalmic surgery sit well above Chinese ones, and Korea's reputation is concentrated in aesthetic and refractive work rather than in complex medical eye disease. If your need is orbital, corneal, vitreoretinal or paediatric, compare institutions and subspecialty depth rather than national reputations, because at that level of complexity the individual unit matters far more than the country.
What should I ask every destination before I book?
Six questions, and they are deliberately country-neutral. Who is the named operating surgeon, what is their subspecialty, and how many of my specific procedure do they perform a year? What exactly is in the quoted price, and what are the named items that would be added — a different lens, a second procedure, an unplanned night, imaging repeated on arrival? What happens, and who pays, if there is a complication or a repeat procedure is needed? What records will I leave with — operative note, implant model and serial number, drug names and lot numbers, imaging in a readable format? Who reviews me at home, and has that person agreed before I fly? And what is the plan if I need to come back? A destination that answers all six in writing is a better bet than a cheaper one that answers three.